Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ibis Biosciences, a majority-owned subsidiary of Isis Pharmaceuticals, has been awarded two new Phase II Small Business Innovation Research or SBIR grants and a new government contract totaling up to approximately $2.8 million.
Subscribe to our email newsletter
The SBIR grants awarded by the National Heart, Lung, and Blood Institute of the National Institutes of Health and the US Army will fund advancements in the Ibis T5000 Biosensor System for new biodefense applications, including the detection and identification of infectious agents within the military blood supply.
Michael Treble, president of Ibis and vice president of Isis, said: “This $2.8 million and other ongoing government contracts will continue to fund advancements in our technology, which we can incorporate into our commercial products for various government, epidemiology and clinical research applications, and eventually into our products targeting larger commercial markets such as clinical diagnostics.”